PPD is further boosting its real-world data offerings with its subsidiary Evidera snapping up Medimix.
The deal, financial details of which were not disclosed, comes three years after Evidera was bought out by PPD, which a year later in 2017 used the company to combine all of its medical affairs research operations (known as MARO) under the real-world research-focused subsidiary.
The addition of Medimix “enhances Evidera’s ability to leverage data to provide real-world evidence and insights for clients,” the company says in a statement.
Its new buy “scans, extracts and synthesizes big data and evidence-based information using a proprietary cloud-based visualization and analytics interface,” according to its blurb, with a focus on hematology and oncology.
In essence, it uses a tech platform to scan across real-world usage (i.e., how patients/medical professionals are using drugs/medical devices) and relays this information back to clients to gain deeper insights across a much larger patient population.
Medimix does this via its LiveTracker, a cloud-based platform it says can “provide robust and comparable real-world evidence in more than 60 countries, including information on market structure, drug awareness and level of adoption, patient profiles, and treatment sequencing and outcomes.”
Evidera said it will leverage the platform and the data it generates to “power more efficient and effective real-world research that addresses burden of illness, resource utilization, safety, patient outcomes and other endpoints.”
“The addition of Medimix will expand our ability to help our clients plan for and generate the evidence needed to optimize the market access and commercial potential of their products,” said Karen Kaucic, M.D., president of Evidera. “We look forward to leveraging the capabilities and resources of Medimix to develop novel approaches to access and maximize the utility of real-world data.”